首页 | 本学科首页   官方微博 | 高级检索  
     

原发鼻腔早期非霍奇金淋巴瘤的长期疗效和预后分析
作者姓名:He YF  Zhang YJ  Li YH  Lin TY  Xia YF  Lu TX  Huang HQ  Jiang WQ  Xian CG  He YJ  Guan ZZ
作者单位:安徽省省立医院肿瘤科;华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心放射治疗科,广东,广州,510060;华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心内科,广东,广州,510060
摘    要:背景与目的:原发鼻腔淋巴瘤具有独特的病理和临床特征,在我国发病率较高,其最佳的治疗方案尚待明确。本文对原发鼻腔非霍奇金淋巴瘤(non-HodgkinQslymphoma,NHL)的早期病例临床特点、治疗和预后情况进行回顾性分析。方法:分析1990年6月至2004年9月中山大学肿瘤防治中心收治的108例初治原发鼻腔早期NHL病例,对其临床资料进行统计分析。全组108例病例均经病理检查和免疫组化明确诊断,其中7例属于B细胞来源。采用Kaplan-Meier方法对临床、病理参数进行单因素生存分析,用Cox模型进行多因素分析。结果:生存患者的中位随访时间为41个月。首程治疗后全组患者近期完全缓解(CR)率为67.6%,综合治疗CR率为80.2%,单纯化疗CR率为29.6%。33例(30.6%)患者有明确的全身播散证据,综合治疗在控制局部、区域淋巴结及全身播散方面均优于单纯化疗。全组病例5年生存率为50.0%。单因素以及多因素分析均显示生存有利的变量因素包括病史大于3个月、病灶不超腔、首程治疗后CR和放化综合治疗。结论:外周T和NK细胞淋巴瘤在原发鼻腔NHL病例中占有较大比例。病史、病变侵犯范围以及首程治疗效果是早期患者生存的主要影响因素。

关 键 词:鼻腔  非霍奇金淋巴瘤  综合疗法  预后因素
文章编号:1000-467X(2006)12-1538-05
收稿时间:2005-11-29
修稿时间:2006-03-17

Primary non-Hodgkin's lymphoma of the nasal cavity at early stage: long-term treatment outcomes and prognostic analyses of 108 cases
He YF,Zhang YJ,Li YH,Lin TY,Xia YF,Lu TX,Huang HQ,Jiang WQ,Xian CG,He YJ,Guan ZZ.Primary non-Hodgkin's lymphoma of the nasal cavity at early stage: long-term treatment outcomes and prognostic analyses of 108 cases[J].Chinese Journal of Cancer,2006,25(12):1538-1542.
Authors:He Yi-Fu  Zhang Yu-Jing  Li Yu-Hong  Lin Tong-Yu  Xia Yun-Fei  Lu Tai-Xiang  Huang Hui-Qiang  Jiang Wen-Qi  Xian Chao-Gui  He You-Jian  Guan Zhong-Zhen
Affiliation:1. State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. R. China ;2. Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou , Guangdong , 510060, P. R. China; 3. Department of Radiation Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, P. R. China
Abstract:BACKGROUND & OBJECTIVE: Primary non-Hodgkin's lymphoma (NHL) of the nasal cavity has unique clinicopathologic features, and optimal treatment regimen remains unclear. This study was to summarize the clinical features, treatment outcomes, and prognostic factors of primary NHL of the nasal cavity at early stage. METHODS: Records of 108 patients with primary NHL of the nasal cavity, consecutively treated at Cancer Center, Sun Yat-sen University from Jun. 1990 to Sep. 2004, were reviewed. All diagnoses were confirmed with pathology and immunochemistry. Seven cases were of B-cell phenotype. Survival prognostic factors were analyzed by Kaplan-Meier method and Cox regression model with SPSS12.0 software. RESULTS: Median follow-up time for survived patients was 41 months. The overall complete remission (CR) rate after primary treatment was 67.6%, and CR rates were 80.2% for the patients received radiochemotherapy and 29.6% for the patients received chemotherapy alone. There were evidences indicating systemic relapse in 33 (30.6%) patients. With regard to the control of local, regional, and systemic failure, radiochemotherapy was better than chemotherapy alone. The 5-year overall survival rate was 50.0% for all patients. Both univariate analysis and multivariate analysis showed that pre-treatment history of more than 3 months, primary lesion limited in the nasal cavity, CR after primary treatment, and radiochemotherapy were favorable prognostic factors. CONCLUSIONS: Nasal cavity is frequently involved by peripheral T- and NK-cell lymphomas. Pre-treatment history of disease, extent of primary lesion involvement, and response to the primary treatment may be independent prognostic factors.
Keywords:Nasal cavity  Non-Hodgkin's lymphoma  Combined modality treatment  Prognostic factors
本文献已被 CNKI 维普 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号